Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Xeris Biopharma Holdings (XERS) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $10.2 million in Q4 2024.

• Quarterly Change in Acquisitions & Divestments fell 31.76% year-over-year to $10.2 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $10.2 million (down 77.25% YoY) and the FY2024 annual result came in at $40.2 million, up 0.59% from the prior year.
• Change in Acquisitions & Divestments retreated to $10.2 million in Q4 2024, from $15.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $34.6 million in Q1 2021 to a low of $5.0 million in Q1 2024.
• A 5-year average of $14.8 million and a median of $11.3 million in 2021 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments tumbled 80.66% — and 2023, when it jumped 117.86%.
• Tracing XERS's Change in Acquisitions & Divestments over 5 years: stood at $17.8 million in 2020, then plunged by 41.14% to $10.5 million in 2021, then fell by 11.43% to $9.3 million in 2022, then soared by 61.29% to $15.0 million in 2023, then plunged by 31.76% to $10.2 million in 2024.
• The last three Change in Acquisitions & Divestments figures came in at $10.2 million (Q4 2024), $15.0 million (Q3 2024), and $10.0 million (Q2 2024), per Business Quant data.